← Back to Search

Other

LOXO-783 alone for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 upto 96 hours postdose of each treatment period
Awards & highlights

Study Summary

This trial will measure how safe and effective a drug is in healthy participants by testing blood levels and assessing how the body handles it. Participation could last up to 63 days.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 upto 96 hours postdose of each treatment period
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 upto 96 hours postdose of each treatment period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf]) of LOXO-783
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LOXO-783

Trial Design

3Treatment groups
Experimental Treatment
Group I: LOXO-783 aloneExperimental Treatment1 Intervention
Single dose of LOXO-783 administered orally.
Group II: LOXO-783 + Cholestyramine 4 hours post doseExperimental Treatment2 Interventions
Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 4 hours.
Group III: LOXO-783 + Cholestyramine 1 hour post doseExperimental Treatment2 Interventions
Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 1 hour.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LOXO-783
2023
Completed Phase 1
~30
Cholestyramine
2018
Completed Phase 4
~340

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,900 Total Patients Enrolled
Loxo Oncology, Inc.Industry Sponsor
67 Previous Clinical Trials
10,168 Total Patients Enrolled
Yingying Guo-Avrutin, MD; PhDStudy DirectorLoxo Oncology, Inc.

Media Library

LOXO-783 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05894928 — Phase 1
Healthy Subjects Research Study Groups: LOXO-783 alone, LOXO-783 + Cholestyramine 1 hour post dose, LOXO-783 + Cholestyramine 4 hours post dose
Healthy Subjects Clinical Trial 2023: LOXO-783 Highlights & Side Effects. Trial Name: NCT05894928 — Phase 1
LOXO-783 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05894928 — Phase 1
Healthy Subjects Patient Testimony for trial: Trial Name: NCT05894928 — Phase 1
~11 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top